Cost considerations Pharmaceutical semaglutide (Wegovy): $1,300-1,500/month without insurance Insurance may cover (varies) Patient assistance programs available Research semaglutide: $150-300/month No insurance No patient assistance User assumes risk Research cagrilintide: $200-400/month Not prescription available yet Higher cost due to limited availability Total CagriSema combination cost (research chemicals): $350-700/month Both peptides at full dose Significant investment Compare to bariatric surgery ($15,000-25,000 upfront) Budget planning: Year 1 (titration + maintenance): $4,200-8,400 Ongoing maintenance: $350-700/month Consider reducing to maintenance doses May need 12-24+ months total Use our peptide cost calculator to budget protocols
This human safety record however limited in scope is a meaningful differentiator when researchers evaluate the preclinical-to-translational potential of synthetic peptides
Cell Metabolism, 27 (5), 1067
Association of p53 with neurodegeneration in Parkinson's disease
Dieckol, a significant antioxidant, serves as the primary bioactive component of purified polyphenolic extract from Ecklonia cava an edible brown alga found mainly in China, South Korea, and Japan (Li et al
When CagriSema becomes available, switching from tirzepatide will be possible but will require medical guidance